|
2025-01-02 |
2024-12-30 |
B
Purchase
|
CHANG NANCY T
Non-Executive Director
Large shareholder
|
7,644,932
+inf%
0.07
USD 499,979
|
7,644,932
+inf%
|
0.07
|
USD 499,979
|
|
|
2024-08-20 |
2024-08-16 |
S
Sale
|
Sorensen Mel
President and CEO
Executive Director
|
67,015
-20.2%
0.07
USD 4,825
|
67,015
-20.2%
|
0.07
|
USD 4,825
|
|
|
2024-02-26 |
2024-02-08 |
B
Purchase
|
Schneid Yair
Large shareholder
|
150,000
+1.9%
0.17
USD 25,650
|
150,000
+1.9%
|
0.17
|
USD 25,650
|
|
|
2024-02-26 |
2024-02-07 |
B
Purchase
|
Schneid Yair
Large shareholder
|
150,000
+1.9%
0.17
USD 25,935
|
150,000
+1.9%
|
0.17
|
USD 25,935
|
|
|
2024-02-26 |
2024-02-07 |
B
Purchase
|
Schneid Yair
Large shareholder
|
25,000
+0.3%
0.17
USD 4,250
|
25,000
+0.3%
|
0.17
|
USD 4,250
|
|
|
2024-02-26 |
2024-02-06 |
B
Purchase
|
Schneid Yair
Large shareholder
|
25,000
+0.3%
0.20
USD 5,025
|
25,000
+0.3%
|
0.20
|
USD 5,025
|
|
|
2024-02-26 |
2024-02-05 |
B
Purchase
|
Schneid Yair
Large shareholder
|
97,402
+1.3%
0.18
USD 17,922
|
97,402
+1.3%
|
0.18
|
USD 17,922
|
|
|
2024-02-26 |
2024-01-30 |
B
Purchase
|
Schneid Yair
Large shareholder
|
335,000
+4.6%
0.18
USD 60,635
|
335,000
+4.6%
|
0.18
|
USD 60,635
|
|
|
2024-02-26 |
2024-01-29 |
B
Purchase
|
Schneid Yair
Large shareholder
|
150,000
+2.1%
0.18
USD 27,000
|
150,000
+2.1%
|
0.18
|
USD 27,000
|
|
|
2023-03-20 |
2023-03-16 |
B
Purchase
|
Bachleda Mark
Chief Commercial Officer
Officer
|
11,000
+inf%
2.25
USD 24,717
|
11,000
+inf%
|
2.25
|
USD 24,717
|
|
|
2023-03-14 |
2023-03-13 |
B
Purchase
|
Degnan Chris
Chief Financial Officer
Officer
|
10,000
+inf%
1.96
USD 19,593
|
10,000
+inf%
|
1.96
|
USD 19,593
|
|
|
2023-03-14 |
2023-03-10 |
B
Purchase
|
Sorensen Mel
President and CEO
Executive Director
|
100,000
+43.1%
1.68
USD 168,120
|
100,000
+43.1%
|
1.68
|
USD 168,120
|
|
|
2021-12-20 |
2021-12-17 |
B
Purchase
|
West Linda
Non-Executive Director
|
20,000
+50.0%
2.74
USD 54,804
|
20,000
+50.0%
|
2.74
|
USD 54,804
|
|
|
2021-09-03 |
2021-09-01 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
47,756
-100.0%
8.47
USD 404,498
|
47,756
-100.0%
|
8.47
|
USD 404,498
|
|
|
2021-06-17 |
2021-06-15 |
B
Purchase
|
West Linda
Non-Executive Director
|
10,000
+33.3%
9.13
USD 91,300
|
10,000
+33.3%
|
9.13
|
USD 91,300
|
|
|
2021-06-04 |
2021-06-02 |
B
Purchase
|
West Linda
Non-Executive Director
|
10,000
+50.0%
8.65
USD 86,511
|
10,000
+50.0%
|
8.65
|
USD 86,511
|
|
|
2021-06-03 |
2021-06-01 |
B
Purchase
|
Alleva Lawrence M
Non-Executive Director
|
4,045
+inf%
8.59
USD 34,741
|
4,045
+inf%
|
8.59
|
USD 34,741
|
|
|
2021-06-02 |
2021-06-01 |
B
Purchase
|
West Linda
Non-Executive Director
|
10,000
+100.0%
8.64
USD 86,381
|
10,000
+100.0%
|
8.64
|
USD 86,381
|
|
|
2021-06-02 |
2021-05-28 |
B
Purchase
|
West Linda
Non-Executive Director
|
10,000
+inf%
8.64
USD 86,410
|
10,000
+inf%
|
8.64
|
USD 86,410
|
|
|
2021-02-19 |
2021-02-18 |
S
Sale
|
Novo Holdings A/S
Large shareholder
|
500,000
-16.9%
10.58
USD 5,290,000
|
500,000
-16.9%
|
10.58
|
USD 5,290,000
|
|
|
2020-11-17 |
2020-11-13 |
B
Purchase
|
Alleva Lawrence M
Non-Executive Director
|
2,325
+58.1%
10.22
USD 23,771
|
2,325
+58.1%
|
10.22
|
USD 23,771
|
|
|
2020-11-16 |
2020-11-13 |
S
Sale
|
Sussman Joel F.
Chief Accounting Officer
Officer
|
10,000
-100.0%
10.32
USD 103,197
|
10,000
-100.0%
|
10.32
|
USD 103,197
|
|
|
2020-11-16 |
2020-11-12 |
S
Sale
|
Sussman Joel F.
Chief Accounting Officer
Officer
|
10,000
-100.0%
10.06
USD 100,627
|
10,000
-100.0%
|
10.06
|
USD 100,627
|
|
|
2020-10-28 |
2020-10-26 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
2,244
-100.0%
15.00
USD 33,660
|
2,244
-100.0%
|
15.00
|
USD 33,660
|
|
|
2020-10-19 |
2020-10-15 |
S
Sale
|
Novo Holdings A/S
Large shareholder
|
450,000
-13.2%
11.00
USD 4,950,000
|
450,000
-13.2%
|
11.00
|
USD 4,950,000
|
|
|
2020-10-07 |
2020-10-06 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
10,536
-100.0%
12.00
USD 126,432
|
10,536
-100.0%
|
12.00
|
USD 126,432
|
|
|
2020-10-07 |
2020-10-05 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
100
-100.0%
12.00
USD 1,200
|
100
-100.0%
|
12.00
|
USD 1,200
|
|
|
2020-06-22 |
2020-06-19 |
S
Sale
|
Novartis Bioventures Ltd
Former 10% Owner
|
1,001,312
-28.9%
8.25
USD 8,260,824
|
1,001,312
-28.9%
|
8.25
|
USD 8,260,824
|
|
|
2020-06-22 |
2020-06-18 |
S
Sale
|
Novartis Bioventures Ltd
Former 10% Owner
|
900
-0.0%
9.04
USD 8,136
|
900
-0.0%
|
9.04
|
USD 8,136
|
|
|
2020-06-17 |
2020-06-17 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
4,622
-0.1%
9.27
USD 42,846
|
4,622
-0.1%
|
9.27
|
USD 42,846
|
|
|
2020-06-17 |
2020-06-16 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
8,600
-0.2%
9.30
USD 79,980
|
8,600
-0.2%
|
9.30
|
USD 79,980
|
|
|
2020-06-17 |
2020-06-15 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
6,164
-0.2%
9.05
USD 55,784
|
6,164
-0.2%
|
9.05
|
USD 55,784
|
|
|
2020-06-12 |
2020-06-12 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
1,500
-0.0%
9.19
USD 13,785
|
1,500
-0.0%
|
9.19
|
USD 13,785
|
|
|
2020-06-12 |
2020-06-11 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
7,200
-0.2%
9.21
USD 66,312
|
7,200
-0.2%
|
9.21
|
USD 66,312
|
|
|
2020-06-12 |
2020-06-10 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
8,532
-0.2%
9.46
USD 80,713
|
8,532
-0.2%
|
9.46
|
USD 80,713
|
|
|
2020-06-09 |
2020-06-09 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
7,000
-0.2%
9.38
USD 65,660
|
7,000
-0.2%
|
9.38
|
USD 65,660
|
|
|
2020-06-09 |
2020-06-08 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
5,659
-0.2%
9.66
USD 54,666
|
5,659
-0.2%
|
9.66
|
USD 54,666
|
|
|
2020-06-09 |
2020-06-05 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
8,652
-0.2%
9.66
USD 83,578
|
8,652
-0.2%
|
9.66
|
USD 83,578
|
|
|
2020-06-04 |
2020-06-04 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
4,088
-0.1%
9.55
USD 39,040
|
4,088
-0.1%
|
9.55
|
USD 39,040
|
|
|
2020-06-04 |
2020-06-03 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
5,208
-0.1%
9.78
USD 50,934
|
5,208
-0.1%
|
9.78
|
USD 50,934
|
|
|
2020-06-04 |
2020-06-02 |
S
Sale
|
Novartis Bioventures Ltd
Large shareholder
|
5,669
-0.2%
9.68
USD 54,876
|
5,669
-0.2%
|
9.68
|
USD 54,876
|
|
|
2020-05-28 |
2020-05-26 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
692
-100.0%
12.00
USD 8,304
|
692
-100.0%
|
12.00
|
USD 8,304
|
|
|
2020-05-22 |
2020-05-21 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
1,174
-100.0%
12.00
USD 14,088
|
1,174
-100.0%
|
12.00
|
USD 14,088
|
|
|
2020-05-22 |
2020-05-20 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
969
-100.0%
12.00
USD 11,628
|
969
-100.0%
|
12.00
|
USD 11,628
|
|
|
2020-05-12 |
2020-05-12 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
671
-100.0%
12.00
USD 8,052
|
671
-100.0%
|
12.00
|
USD 8,052
|
|
|
2020-05-12 |
2020-05-11 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
185
-100.0%
12.00
USD 2,220
|
185
-100.0%
|
12.00
|
USD 2,220
|
|
|
2020-05-12 |
2020-05-08 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
5,102
-100.0%
12.00
USD 61,224
|
5,102
-100.0%
|
12.00
|
USD 61,224
|
|
|
2020-05-07 |
2020-05-07 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
2,059
-100.0%
12.00
USD 24,709
|
2,059
-100.0%
|
12.00
|
USD 24,709
|
|
|
2020-05-07 |
2020-05-06 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
1,489
-100.0%
12.00
USD 17,868
|
1,489
-100.0%
|
12.00
|
USD 17,868
|
|
|
2020-05-07 |
2020-05-05 |
PS
Planned sale
|
HOLMLUND JON T
Chief Medical Officer
Officer
|
3,064
-100.0%
12.16
USD 37,258
|
3,064
-100.0%
|
12.16
|
USD 37,258
|
|
|
2019-12-17 |
2019-12-13 |
B
Purchase
|
Alleva Lawrence M
Non-Executive Director
|
4,000
+inf%
9.78
USD 39,139
|
4,000
+inf%
|
9.78
|
USD 39,139
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Clarus IV-A, L.P.
Large shareholder
|
19,423
+17.5%
12.00
USD 233,076
|
19,423
+17.5%
|
12.00
|
USD 233,076
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Clarus IV-A, L.P.
Large shareholder
|
97,131
+17.5%
12.00
USD 1,165,572
|
97,131
+17.5%
|
12.00
|
USD 1,165,572
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Clarus IV-A, L.P.
Large shareholder
|
52,660
+17.5%
12.00
USD 631,920
|
52,660
+17.5%
|
12.00
|
USD 631,920
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Clarus IV-A, L.P.
Large shareholder
|
80,786
+17.5%
12.00
USD 969,432
|
80,786
+17.5%
|
12.00
|
USD 969,432
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Novo Holdings A/S
SEE REMARKS
Large shareholder
|
500,000
+17.2%
12.00
USD 6,000,000
|
500,000
+17.2%
|
12.00
|
USD 6,000,000
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Blackstone Clarus GP L.P.
Large shareholder
|
19,423
+17.5%
12.00
USD 233,076
|
19,423
+17.5%
|
12.00
|
USD 233,076
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Blackstone Clarus GP L.P.
Large shareholder
|
97,131
+17.5%
12.00
USD 1,165,572
|
97,131
+17.5%
|
12.00
|
USD 1,165,572
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Blackstone Clarus GP L.P.
Large shareholder
|
52,660
+17.5%
12.00
USD 631,920
|
52,660
+17.5%
|
12.00
|
USD 631,920
|
|
|
2019-11-14 |
2019-11-12 |
B
Purchase
|
Blackstone Clarus GP L.P.
Large shareholder
|
80,786
+17.5%
12.00
USD 969,432
|
80,786
+17.5%
|
12.00
|
USD 969,432
|
|
|
2019-11-12 |
2019-11-12 |
B
Purchase
|
Sofinnova Venture Partners IX, L.P.
Large shareholder
|
750,000
+32.1%
12.00
USD 9,000,000
|
750,000
+32.1%
|
12.00
|
USD 9,000,000
|
|
|
2019-11-12 |
2019-11-12 |
B
Purchase
|
New Enterprise Associates 14, L.P.
Large shareholder
|
416,666
+10.6%
12.00
USD 4,999,992
|
416,666
+10.6%
|
12.00
|
USD 4,999,992
|
|
|
2019-11-12 |
2019-11-12 |
B
Purchase
|
Novartis Bioventures Ltd
Large shareholder
|
250,000
+7.6%
12.00
USD 3,000,000
|
250,000
+7.6%
|
12.00
|
USD 3,000,000
|
|
